Clinical

Washington State's Veterinary Association Announces Annual Award Winners

Thursday, October 21, 2021 - 10:42pm

REDMOND, Wash., Oct. 21, 2021 /PRNewswire/ --The Washington State Veterinary Medical Association (WSVMA) held the Pacific Northwest Veterinary Conference Oct. 1 Oct 3 in a virtual, online platform.

Key Points: 
  • REDMOND, Wash., Oct. 21, 2021 /PRNewswire/ --The Washington State Veterinary Medical Association (WSVMA) held the Pacific Northwest Veterinary Conference Oct. 1 Oct 3 in a virtual, online platform.
  • Veterinarians and veterinary staff were honored at WSVMA's award ceremonies on Friday, Oct. 1.
  • The award is presented in recognition of an outstanding career in veterinary medicine and contributions made to their practice, stakeholders, and other service directly benefitting their community.
  • Visit the WSVMA Web site, www.wsvma.org , to learn more about the association, veterinary medicine, and animal care.

Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)

Thursday, October 21, 2021 - 5:00pm

Horizon Therapeutics plc (Nasdaq: HZNP) today announced additional data supporting the long-term efficacy of TEPEZZA for the treatment of TED.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced additional data supporting the long-term efficacy of TEPEZZA for the treatment of TED.
  • Thyroid Eye Disease can take a significant toll on people who are living with the disease, affecting them both physically and emotionally.
  • Of the OPTIC patients who received TEPEZZA and completed the 48-week follow-up, 90% (18/20) received no additional therapy as of Week 120.
  • One patient received TEPEZZA 16 months after the last dose and one had eyelid surgery a year after the last dose.

QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions

Tuesday, October 19, 2021 - 9:05pm

QIAGEN will focus on regions that face a high burden of the disease, and where getting access to lab infrastructure and resources for testing are limited.

Key Points: 
  • QIAGEN will focus on regions that face a high burden of the disease, and where getting access to lab infrastructure and resources for testing are limited.
  • With QIAreach QuantiFERON-TB we have taken a great step towards leaving no one behind when facing a deadly disease like tuberculosis that is preventable and curable.
  • A quantum leap from the traditional TB skin test, QuantiFERON-TB uses blood samples to test for interferon-gamma molecules released from T-cells that have come into contact with TB bacteria.
  • QIAreach QuantiFERON-TB runs these tests on the digital eHub and eStick system, a true walkaway solution with random access and no calibration or maintenance.

Vibrent Health and Virginia Commonwealth University Launch a Global Twin Research Platform to Enable Collaboration, Accelerate Discoveries in Genetic Research and Precision Medicine

Tuesday, October 19, 2021 - 2:22pm

Large scale longitudinal research of twin pairs can provide unique scientific data about genetic and environmental influences underlying individual differences in twins.

Key Points: 
  • Large scale longitudinal research of twin pairs can provide unique scientific data about genetic and environmental influences underlying individual differences in twins.
  • The interoperability of the platform with many broad sources of data represents novel advancements in twin research.
  • Vibrent Healths mission is to accelerate health research to optimize human health through precision technology and digital tools that empower participant engagement, research analytics and research management for researchers, research organizations and research participants.
  • Through its Digital Health Solutions Platform, the company provides a large-scale versatile platform for health research.

OnKure Therapeutics Appoints Jennifer R. Diamond, M.D., as Chief Medical Officer

Thursday, October 14, 2021 - 12:00pm

OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Jennifer R. Diamond, M.D., as Chief Medical Officer.

Key Points: 
  • OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Jennifer R. Diamond, M.D., as Chief Medical Officer.
  • We are very pleased to welcome Jennifer to our growing leadership team, said Tony Piscopio, Ph.D., Co-Founder, President and Chief Executive Officer of OnKure.
  • In addition to serving in her role at OnKure, Dr. Diamond works in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus as a breast cancer medical oncologist and Associate Professor of Medicine.
  • I am thrilled to be joining OnKure at such an important time in the Companys growth, said Dr. Diamond.

Topelia Australia launches US$25M Series A call for COVID-19 ATT Ziverdox

Thursday, October 14, 2021 - 6:45am

- Based on current research, the ATT provides an inexpensive and medically efficacious treatment for the prevention and early treatment of COVID-19.

Key Points: 
  • - Based on current research, the ATT provides an inexpensive and medically efficacious treatment for the prevention and early treatment of COVID-19.
  • The company said: "Topelia proposes to offer the ATT treatment alongside the current vaccination program to treat and vaccinate our way out of this pandemic.
  • The novel Antiviral Triple Therapy, to be branded as Ziverdox, comprises TGA-approved medications prescribed for decades with exceptional safety profiles.
  • Topelia Australia was founded based on the wealth of experience in commercialising the ground-breaking triple therapy cure for peptic ulcers which has saved over 18 thousand lives in Australia alone.

Shina Systems Ltd. integrates iCAD's ProFound AI into its 3Di PACS Viewer

Wednesday, October 13, 2021 - 4:00pm

MONTEBELLO, N.Y., Oct. 13, 2021 /PRNewswire-PRWeb/ -- Shina Systems Ltd., the leading developer of advanced clinical image management, visualization and analysis software, announced today that it will integrate ProFound AI into its 3Di PACS viewer.

Key Points: 
  • MONTEBELLO, N.Y., Oct. 13, 2021 /PRNewswire-PRWeb/ -- Shina Systems Ltd., the leading developer of advanced clinical image management, visualization and analysis software, announced today that it will integrate ProFound AI into its 3Di PACS viewer.
  • 3Di Enterprise PACS is a cloud-based, innovative solution with a comprehensive package of viewers and applications to suit any clinical imaging need.
  • "There is really a lot to be excited about with this partnership," said Elad Arad, VP Business Development & COO of Shina Systems.
  • About Shina Systems Ltd: Shina develops and markets clinical image management, cloud PACS and imaging analysis application software.

Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day

Wednesday, October 13, 2021 - 12:45pm

WALTHAM, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, hosts its first Research and Development Day today focused on the Company’s co-lead development programs for rare muscle diseases, Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). “The Muscle to Move to the Clinic” live virtual event (8:00-10:30 a.m. ET) as well as the replay and slide presentation are available at https://investors.dyne-tx.com/events/event-details/dyne-rd-day.

Key Points: 
  • For its DMD program, Dyne intends to initiate a global, placebo-controlled, multiple-ascending dose (MAD) clinical trial to evaluate DYNE-251 in patients with mutations amenable to exon 51 skipping.
  • The Company also intends to initiate a global, placebo-controlled, MAD clinical trial evaluating DYNE-101 in adult patients with DM1.
  • Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.
  • However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

ENA University Pathways Debut to Support Emergency Nursing Careers

Tuesday, October 12, 2021 - 4:18pm

SCHAUMBURG, Ill., Oct. 12, 2021 /PRNewswire/ -- ENA University , the Emergency Nurses Association's center of emergency nursing education excellence, expanded its innovative offerings Tuesday with the debut of the new ENA University Pathways.

Key Points: 
  • SCHAUMBURG, Ill., Oct. 12, 2021 /PRNewswire/ -- ENA University , the Emergency Nurses Association's center of emergency nursing education excellence, expanded its innovative offerings Tuesday with the debut of the new ENA University Pathways.
  • Nurses who register for an ENA University Pathway have three years to complete courses and receive accredited continuing education credits.
  • Howard also encouraged hospital leaders to explore how ENA University Pathways can support their ED nurses by creating a consistent journey with career development benchmarks.
  • The Emergency Nurses Association is the premier professional nursing association dedicated to defining the future of emergency nursing through advocacy, education, research, innovation, and leadership.

Global Fasciitis Clinical Trials Landscape Report 2021 - ResearchAndMarkets.com

Monday, October 11, 2021 - 12:14pm

The "Fasciitis - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fasciitis - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Fasciitis - Global Clinical Trials Review, H2, 2021" provides an overview of Fasciitis Clinical trials scenario
    This report provides top line data relating to the clinical trials on Fasciitis.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    the report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    the report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Clinical Trials by G7 Countries: Proportion of Fasciitis to Musculoskeletal Disorders Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Fasciitis to Musculoskeletal Disorders Clinical Trials